Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | ACACA | Q13085 | 2/20 | 0.35 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5248989 | 0.93 | RAMP1 (0.42) | ACACBACACARAMP1CALCRLTEAD1 | |
| SCHEMBL3282588 | 0.89 | ACACB (0.39) | ACACBACACATEAD1L3MBTL3L3MBTL1 | |
| SCHEMBL3278696 | 0.83 | ACACB (0.36) | ACACBACACATEAD1L3MBTL3L3MBTL1 | |
| SCHEMBL5660550 | 0.83 | CALCA (0.40) | ACACBACACA | |
| SCHEMBL5659967 | 0.83 | CALCA (0.40) | ACACBACACA | |
| SCHEMBL4849662 | 0.82 | RAMP1 (0.41) | RAMP1CALCRLL3MBTL3L3MBTL1KDM4E | |
| SCHEMBL5250813 | 0.80 | CCR3 (0.38) | ACACBACACAL3MBTL3L3MBTL1KDM4E | |
| SCHEMBL5249986 | 0.78 | CCR3 (0.37) | ACACBACACAL3MBTL3L3MBTL1KDM4E | |
| SCHEMBL3285188 | 0.76 | CCR5 (0.41) | ACACBACACAL3MBTL3L3MBTL1ALDH1A1 | |
| SCHEMBL3284870 | 0.76 | CCR5 (0.41) | ACACBACACAL3MBTL3L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | RUDOLF KLAUS | 2007-10-25 | — | — | US | claimed |
| EP-1833484-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | Boehringer Ingelheim International GmbH (DE) | 2007-09-19 | — | — | EP | claimed |
| WO-2006069754-A9 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-08-09 | — | — | WO | claimed |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | claimed |
| WO-2006069754-A1 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | WO | claimed |
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | RUDOLF KLAUS | 2007-10-25 | — | — | US | disclosed |
| WO-2006069754-A9 | USE OF CGRP ANTAGONISTS IN TREATMENT AND PREVENTION OF HOT FLUSHES IN PROSTATE CANCER PATIENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-08-09 | — | — | WO | disclosed |
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154921-A1 | Use of CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, CALCR | ACACB 2927/4885ACACA 2316/4885RAMP1 314/4885 |
| US-20070249592-A1 | Use of selected CGRP antagonists in treatment and prevention of hot flushes in prostate cancer patients | CALCA, CALCB, BDKRB2 | ACACB 3022/4885ACACA 2368/4885RAMP1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.